A startling 89 per cent of desmoplastic melanoma patients in a nationwide clinical study responded to immunotherapy (pembrolizumab) alone, indicating that many
Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to immunotherapy (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination therapies and achieve cancer control with this approach to treatment.
Immunotherapy Shows Exceptional Response Rates in Melanoma Patients miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
One new home in M/I Homes’ Heritage at Neel Ranch community has an especially meaningful purpose. More than $200,000 from the sale of the Mooresville home will benefit Pelotonia, a